SAN FRANCISCO, CA — May 29, 2002 —
Portal vein invasion (PVI), seen frequently in patients with hepatocellular carcinoma, can be prevented in half treated with vitamin K, researchers say.
They presented their results here at the 103rd annual meeting of the American Gastroenterological Association and Digestive Disease Week (DDW), held May 19-23.
Diagnosis of PVI is a frequent event after diagnosis of liver cancer. Dr. Yukihiro Koike, of Kanto Cho Hospital, and coworkers previously showed a close association between levels of des-g-carboxy-prothrombin (DCP) in serum and development of portal invasion in patients with hepatocellular carcinoma.
In Dr. Koike’s study, 120 patients were treated with ablation, embolization, or both at University of Tokyo or its affiliated hospitals between February 1999 and November 2001. All patients enrolled had low serum levels of DCP (60 IU/L or more). Half of patients were randomized to receive oral vitamin K-II at a dose of 45 mg a day.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!